Nanostructured Lipid Carriers: New Insight for Cancer Therapy

Q3 Engineering

Nanoscience and Nanotechnology - Asia Pub Date : 2022-05-23 DOI:10.2174/2210681212666220523123316

Manasi Jiwankar, Vidya P. Sabale

{"title":"Nanostructured Lipid Carriers: New Insight for Cancer Therapy","authors":"Manasi Jiwankar, Vidya P. Sabale","doi":"10.2174/2210681212666220523123316","DOIUrl":null,"url":null,"abstract":"\n\nCancer is a life-threatening disease that is associated with persistent tissue injury and uncontrolled cell growth. The treatments available to treat cancer include chemotherapy, surgery, and radiation therapy. These treatments are utilized in combination while the most preferred treatment is chemotherapy. Because of the non-specificity of anticancer drugs, they kill healthy cells along with cancer cells, which lead to severe side effects. To minimize such limitations associated with conventional chemotherapy, nanostructured lipids carriers (NLCs) can be developed. These are the nanocarriers consisting of a mixture of solid and liquid lipids and surfactants. Lipids utilized in the formulation of NLCs are biocompatible and biodegradable. NLCs ensure high drug payload, less drug expulsion, and more stability on storage. NLCs enhance the aqueous solubility of lipophilic anticancer drugs. Their surface modification can help to overcome drug resistance in cancer therapy. Controlled and targeted drug delivery of anticancer drugs can be possible by formulating them as NLCs. NLCs can play an important role in targeting anticancer drugs by different mechanisms. This review highlights types, formulation methods, characterization of nanostructured lipid carriers, and strategies to achieve targeted release of anticancer drugs loaded in NLCs.\n","PeriodicalId":38913,"journal":{"name":"Nanoscience and Nanotechnology - Asia","volume":"12 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanoscience and Nanotechnology - Asia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2210681212666220523123316","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Engineering","Score":null,"Total":0}

引用次数: 0

Abstract

Cancer is a life-threatening disease that is associated with persistent tissue injury and uncontrolled cell growth. The treatments available to treat cancer include chemotherapy, surgery, and radiation therapy. These treatments are utilized in combination while the most preferred treatment is chemotherapy. Because of the non-specificity of anticancer drugs, they kill healthy cells along with cancer cells, which lead to severe side effects. To minimize such limitations associated with conventional chemotherapy, nanostructured lipids carriers (NLCs) can be developed. These are the nanocarriers consisting of a mixture of solid and liquid lipids and surfactants. Lipids utilized in the formulation of NLCs are biocompatible and biodegradable. NLCs ensure high drug payload, less drug expulsion, and more stability on storage. NLCs enhance the aqueous solubility of lipophilic anticancer drugs. Their surface modification can help to overcome drug resistance in cancer therapy. Controlled and targeted drug delivery of anticancer drugs can be possible by formulating them as NLCs. NLCs can play an important role in targeting anticancer drugs by different mechanisms. This review highlights types, formulation methods, characterization of nanostructured lipid carriers, and strategies to achieve targeted release of anticancer drugs loaded in NLCs.

查看原文本刊更多论文

纳米结构脂质载体:癌症治疗的新见解

癌症是一种危及生命的疾病，与持续的组织损伤和不受控制的细胞生长有关。现有的治疗癌症的方法包括化疗、手术和放射治疗。这些治疗是联合使用的，而最首选的治疗是化疗。由于抗癌药物的非特异性，它们在杀死癌细胞的同时杀死健康细胞，这导致了严重的副作用。为了尽量减少与传统化疗相关的这些限制，可以开发纳米结构脂质载体(nlc)。这些是由固体和液体脂质和表面活性剂的混合物组成的纳米载体。nclc制剂中使用的脂质具有生物相容性和可生物降解性。NLCs确保高药物有效载荷，更少的药物排出，更稳定的存储。NLCs增强了亲脂性抗癌药物的水溶性。它们的表面修饰有助于克服癌症治疗中的耐药性。通过将抗癌药物配制成NLCs，可以实现抗癌药物的控制和靶向递送。NLCs可以通过不同的机制在靶向抗癌药物中发挥重要作用。本文综述了纳米结构脂质载体的类型、制备方法、表征以及实现nclc中抗癌药物靶向释放的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanoscience and Nanotechnology - Asia Engineering-Engineering (all)

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Nanoscience & Nanotechnology-Asia publishes expert reviews, original research articles, letters and guest edited issues on all the most recent advances in nanoscience and nanotechnology with an emphasis on research in Asia and Japan. All aspects of the field are represented including chemistry, physics, materials science, biology and engineering mainly covering the following; synthesis, characterization, assembly, theory, and simulation of nanostructures (nanomaterials and assemblies, nanodevices, nano-bubbles, nano-droplets, nanofluidics, and self-assembled structures), nanofabrication, nanobiotechnology, nanomedicine and methods and tools for nanoscience and nanotechnology.